Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica
In short
The U.S. Food and Drug Administration has granted regulatory approval to broaden the clinical applications of the drug. Through this decision, the pharmaceutical company can now market the medication specifically for treating polymyalgia rheumatica. This regulatory milestone formally incorporates the inflammatory disorder into the therapeutic's authorized indications.
Key points
- Cosentyx is now officially authorized for the treatment of polymyalgia rheumatica.: Cosentyx is now officially authorized for the treatment of polymyalgia rheumatica.
- Novartis has expanded the authorized clinical indications for its therapeutic portfolio.: Novartis has expanded the authorized clinical indications for its therapeutic portfolio.
- Patients with this inflammatory disorder now have an approved treatment option.: Patients with this inflammatory disorder now have an approved treatment option.